Leerink Partners Maintains Cytokinetics at Outperform, Lowers Price Target
Leerink Partners has maintained its 'Outperform' rating on Cytokinetics while adjusting its price target downward from $103 to $100.
Stocks · News reference
RBC Capital Markets Comments on Cytokinetics' Myqorzo Revenue Potential
RBC Capital Markets issued commentary suggesting that Cytokinetics' product, Myqorzo, could begin to positively impact the company's revenue starting in 2027.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100
Cytokinetics Reports Third Quarter 2026 Financial Results
Cytokinetics reported its third-quarter 2026 financial results, exceeding revenue expectations and providing a business update on its clinical pipeline.
Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate
Cytokinetics Announces Participation in Upcoming November Investor Conferences
Cytokinetics, Incorporated announced that its management team will participate in three investor conferences throughout November 2026.
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions
Cytokinetics, Incorporated announced it will present three abstracts, including two late-breaking oral presentations, at the upcoming Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago.